Rpd3 inhibitors belong to a distinctive class of chemical compounds that exhibit the ability to modulate the activity of the Rpd3 enzyme. The Rpd3 enzyme, also known as histone deacetylase, plays a crucial role in the regulation of gene expression by catalyzing the removal of acetyl groups from lysine residues on histone proteins. By inhibiting the function of Rpd3, these compounds interfere with the deacetylation process, thereby affecting the overall acetylation status of histones. This modulation of histone acetylation patterns can subsequently influence chromatin structure, DNA accessibility, and gene transcription. Rpd3 inhibitors typically exert their effects by binding to the catalytic site of the enzyme, disrupting its enzymatic activity.
The specific mechanisms of action and structural features can vary among different Rpd3 inhibitors, leading to variations in their potency and selectivity. The study of Rpd3 inhibitors has gained significant attention in the field of molecular biology and biochemistry, as they provide valuable tools for investigating the role of histone acetylation in various biological processes. By modulating histone acetylation, Rpd3 inhibitors offer insights into the epigenetic regulation of gene expression, chromatin remodeling, and cellular differentiation. Their unique chemical properties make them indispensable in research endeavors aimed at unraveling the intricate mechanisms governing gene regulation at the molecular level.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
Trichostatin A is a natural product and a potent inhibitor of RpdIt binds to the active site of Rpd3, preventing its deacetylase activity. It has been widely used as a research tool to study histone acetylation and gene regulation. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $130.00 $270.00 | 37 | |
A HDAC inhibitor that targets multiple HDACs, including RpdIt binds to the zinc ion in the catalytic site of Rpd3, inhibiting its deacetylase activity. SAHA has shown promise in cancer therapy by promoting cell differentiation and apoptosis. | ||||||
Panobinostat | 404950-80-7 | sc-208148 | 10 mg | $196.00 | 9 | |
LBH589 is a potent pan-HDAC inhibitor that targets multiple HDACs, including RpdIt inhibits Rpd3's deacetylase activity and has been investigated as an anticancer agent, particularly in hematological malignancies. | ||||||
PCI-24781 | 783355-60-2 | sc-364565 sc-364565A | 5 mg 50 mg | $182.00 $1330.00 | 1 | |
PCI-24781 is a selective inhibitor of Rpd3 and other HDACs. It has shown anticancer activity in research studies and is being investigated for various cancers. | ||||||
Mocetinostat | 726169-73-9 | sc-364539 sc-364539B sc-364539A | 5 mg 10 mg 50 mg | $210.00 $242.00 $1434.00 | 2 | |
Mocetinostat is a Rpd3 inhibitor thay may affect solid tumors and hematological malignancies. It inhibits Rpd3-mediated histone deacetylation, leading to altered gene expression. | ||||||
Belinostat | 414864-00-9 | sc-269851 sc-269851A | 10 mg 100 mg | $153.00 $561.00 | ||
PXD101 is an inhibitor of Rpd3's deacetylase activity and promotes histone acetylation, leading to altered gene expression. | ||||||